Assessment of breast cancer immunohistochemistry and tumor characteristics in Nigeria

Table 1 Clinico-pathological and molecular characteristics of the breast cancer patients (259)

Histologic type	Frequency	Percentage
Invasive ductal carcinoma	258	99.6
Invasive lobular carcinoma	1	0.4
Grading
I	62	23.9
II	131	50.6
III	66	25.5
Tumour size
< 2.0 cm	62	23.9
2-5 cm	131	50.6
> 5.0 cm	66	25.5
Lymph node involvement
No	22	8.5
1-3	196	75.7
≥ 4	41	15.8
Hormonal receptors
ER + ve	113	43.6
ER - ve	52	20.1
PR + ve	42	16.2
PR - ve	12	4.6
HER/2 neu + ve	23	8.9
HER/2 neu - ve	17	6.6
Total	259	100

ER: Estrogen receptor; PR: Progesterone receptor; Human epidermal growth factor receptor-2.

Table 2 Association of estrogen receptor and progesterone receptor with prognostic markers (n = 259)

Age	Hormonal receptors						Total	P value
	ER + ve	ER - ve	PR + ve	PR - ve	HER/2 neu + ve	HER/2 neu - ve
< 50	73 (50.70%)	17 (11.80%)	34 (23.60%)	9 (6.30%)	8 (5.60%)	3 (2.10%)	144	0.01
≥ 50	40 (34.80%)	35 (30.40%)	8 (7.00%)	3 (2.60%)	15 (13.00%)	14 (12.20%)	115
Grading
I	35 (56.50%)	18 (29.00%)	3 (4.80%)	2 (3.20%)	3 (4.80%)	1 (1.60%)	62	0.02
II	55 (42.00%)	23 (17.60%)	29 (22.10%)	5 (3.80%)	13 (9.90%)	6 (4.60%)	131
III	23 (34.80%)	11 (16.70%)	10 (15.20%)	5 (7.60%)	7 (10.60%)	10 (15.20%)	66
Tumour size
< 2.0 cm	35 (56.50%)	18 (29.00%)	3 (4.80%)	2 (3.20%)	3 (4.80%)	1 (1.60%)	62	0.02
2-5 cm	55 (42.00%)	23 (17.60%)	29 (22.10%)	5 (3.80%)	13 (9.90%)	6 (4.60%)	131
> 5.0 cm	23 (34.80%)	11 (16.70%)	10 (15.20%)	5 (7.60%)	7 (10.60%)	10 (15.20%)	66
Lymph node involvement
No	11 (50.00%)	3 (13.60%)	3 (13.60%)	2 (9.10%)	2 (9.10%)	1 (4.50%)	22	0.03
1-3	86 (43.90%)	43 (21.90%)	34 (17.30%)	6 (3.10%)	19 (9.70%)	8 (4.10%)	196
≥ 4	16 (39.00%)	6 (14.60%)	5 (12.20%)	4 (9.80%)	2 (4.90%)	8 (19.50%)	41

ER: Estrogen receptor; PR: Progesterone receptor; HER/2 neu: Human epidermal growth factor receptor-2.

Table 3 Bi-variate correlation of clinicopathological parameters and hormonal receptors

Clinic pathologic feature	Estimators	Hormonal receptors
		ER + ve	ER - ve	PR + ve	PR - ve	Her-2 + ve	Her-2 - ve
Age	R	-0.159a	0.231b	-0.224b	-0.086	0.131a	0.202b
	P value	0.01	0.01	0.01	0.167	0.036	0.001
Grading	R	-0.144b	-0.101	0.089	0.07	0.067	0.184b
	P value	0.015	0.087	0.133	0.236	0.26	0.002
Tumour size	R	-0.144a	-0.101	0.089	0.07	0.067	0.184b
	P value	0.015	0.087	0.133	0.236	0.26	0.002
Lymph node	R	-0.051	-0.018	-0.024	0.045	-0.047	0.184b
	P value	0.401	0.761	0.689	0.455	0.438	0.002
Total		259	259	259	259	259	259

^a: Strongly significant.

^b: Significant.

ER + ve: = Estrogen receptor positive; ER - ve = Estrogen receptor negative; PR + ve =Progesterone receptor positive; PR - ve =Progesterone receptor negative, HER/2 neu + ve= Human epidermal growth factor receptor-2 positive, HER/2 neu - ve= Human epidermal growth factor receptor-2 negative.

Table 4 Multivariate logistic regression analysis of hormonal receptor and age patients

Hormonal receptors		P value	OR	95% confidence interval
				Lower bound	Upper bound
ER + ve	< 50 yr	0.001	8.517	2.309	31.413
	≤ 50 yr	1
ER - ve	< 50 yr	0.243	2.267	0.573	8.965
	≤ 50 yr	1
PR + ve	< 50 yr	0	19.833	4.58	85.883
	≤ 50 yr	1
PR - ve	< 50 yr	0.004	14	2.3	85.218
	≤ 50 yr	1
HER/2 neu + ve	< 50 yr	0.238	2.489	0.548	11.308
	≤ 50 yr	1

ER: Estrogen receptor; PR: Progesterone receptor; OR: Odd ration; HER/2 neu: Human epidermal growth factor receptor-2.

Table 5 Multivariate logistic regression analysis of hormonal receptor and tumor grading

Hormonal receptors	Grading	P value	OR	95% confidence interval
ER + ve	Grade I	0.012	15.217	1.823	127.02
	Grade II	0.016	3.986	1.296	12.252
	Grade III	1
ER - ve	Grade I	0.012	16.364	1.835	145.95
	Grade II	0.049	3.485	1.007	12.057
	Grade III	1
PR + ve	Grade I	0.375	3	0.265	33.974
	Grade II	0.013	4.833	1.397	16.725
	Grade III	1
PR - ve	Grade I	0.301	4	0.288	55.471
	Grade II	0.532	1.667	0.336	8.258
	Grade III	1
HER/2 neu + ve	Grade I	0.246	4.286	0.366	50.197
	Grade II	0.105	3.095	0.789	12.144
	Grade III	1

ER: Estrogen receptor; PR: Progesterone receptor; OR: Odd ration; HER/2 neu: Human epidermal growth factor receptor-2.